Core Insights - Amneal Pharmaceuticals reported revenue of $784.51 million for the quarter ended September 2025, reflecting an 11.7% increase year-over-year and a surprise of +1.41% over the Zacks Consensus Estimate of $773.6 million [1] - The company's EPS for the quarter was $0.17, up from $0.16 in the same quarter last year, resulting in a surprise of +30.77% compared to the consensus EPS estimate of $0.13 [1] Revenue Breakdown - Affordable Medicines Segment generated net revenue of $460.74 million, slightly below the estimated $465.18 million, but still showing a year-over-year increase of +7.8% [4] - AvKARE Segment reported net revenue of $198.53 million, exceeding the average estimate of $192.83 million, with a significant year-over-year growth of +24.5% [4] - Specialty Segment achieved net revenue of $125.24 million, surpassing the average estimate of $114.52 million, marking an +8.3% increase year-over-year [4] Stock Performance - Over the past month, Amneal's shares have returned +0.5%, while the Zacks S&P 500 composite has seen a +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Amneal Pharmaceuticals reported revenue of $724.51 million for the quarter ended June 2025, marking a year-over-year increase of 3.2% [1] - The earnings per share (EPS) for the same period was $0.25, compared to $0.16 a year ago, indicating a significant improvement [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $725.6 million, resulting in a surprise of -0.15% [1] - The company achieved an EPS surprise of +38.89%, with the consensus EPS estimate being $0.18 [1] Revenue Breakdown - Affordable Medicines Segment generated net revenue of $433.43 million, which was below the average estimate of $453.34 million, reflecting a year-over-year change of +1.4% [4] - AvKARE Segment reported net revenue of $163.04 million, falling short of the estimated $182.65 million, representing a year-over-year decline of -4.3% [4] - Specialty Segment achieved net revenue of $128.04 million, exceeding the average estimate of $108.11 million, with a year-over-year increase of +23.1% [4] Stock Performance - Over the past month, Amneal's shares have returned -5.4%, contrasting with the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]